David Roblin

With little momentum in developing new new antibiotics to fight antimicrobial resistance, the time is now to emphasize "push" and "pull" incentives and demonstrate how innovation in this area will lead to patient benefit and economic reward.

There is a lack of push in the development of new antibiotics while anti-microbial resistance is a priority topic in healthcare policy and on the political agenda.